知搜-全球专利检索

  1. 登录
  2. 注册
发明公开
CN103505444A 吉马酮在制备用于治疗肝癌药物中的应用 无效 - 驳回

吉马酮在制备用于治疗肝癌药物中的应用
摘要：
本发明提供了吉马酮作为治疗肝癌药物的应用，吉马酮对HepG2细胞的细胞毒性实验结果显示，IC50约160μm，流式细胞仪检测吉马酮对肝癌HepG2细胞周期和凋亡的影响实验结果显示，吉马酮能诱导HepG2细胞G2/M周期阻滞并促进细胞凋亡。通过不同浓度吉马酮处理HepG2细胞，检测周期阻滞、凋亡相关蛋白表达情况，结果显示吉马酮通过下调cyclinB1和CDK1蛋白诱导HepG2细胞G2/M周期阻滞，通过p53调控的线粒体凋亡途径促进HepG2细胞凋亡。本发明检测了吉马酮处理后的HepG2细胞ROS产量，结果显示吉马酮可以促进ROS产量的上升，可以造成细胞氧化性损伤。
摘要（英）：

The invention provides an application of germacrone as a liver cancer treatment medicine. Results of experiments about the cytotoxicity of germacrone to HepG2 cells show that IC50 is about 160mum; and results of experiments about the detection of the influences of germacrone to liver cancer HepG2 cell cycle and apoptosis by using a flow cytometer show that germacrone can induce HepG2 cell G2/M cycle arrest and promote the cell apoptosis. Results of the detection of the cycle arrest and the apoptosis related protein expression situation by processing HepG2 cells through different concentrations of germacrone show that germacrone induces the HepG2 cell G2/M cycle arrest by reducing the cyclinB1 and CDK1 proteins and promotes the HepG2 cell apoptosis through p53 regulated mitochondrial apoptosis. Results of the detection of the ROS output of the germacrone processed HepG2 cells show that germacrone can promote the rise of the ROS output and cause the oxidative damages of the cells.

0/0